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  ABSTRACT  
  
Background: Knowledge of hepatitis C virus (HCV) is believed to be important in altering risk 
behaviour, improving engagement in care, and promoting willingness to initiate HCV treatment. 
We assessed factors associated with HCV knowledge and treatment willingness amongst people 
who inject drugs (PWID) in an era of direct acting antivirals.   
  
Methods: Data were derived from three prospective cohort studies of PWID in Vancouver, 
Canada, between June 2014 and May 2015. HCV knowledge and treatment willingness were 
assessed using a Likert scale. Multivariable linear regression identified factors associated with 
higher HCV knowledge and treatment willingness.  
 
Results: Amongst 630 participants, mean scores for HCV knowledge and treatment willingness 
were 25.41 (standard deviation [SD]: 2.52) out of 30, and 6.83 (SD: 1.83) out of 10, respectively. 
In multivariable analyses, Caucasian ancestry (adjusted linear regression model estimate [β] 0.50; 
95% confidence interval [CI] 0.17, 0.82), employment (β 0.76; 95% CI: 0.38, 1.13), diagnosed 
mental health disorder (β 0.44; 95% CI: 0.11, 0.78) and previous HCV treatment (β 0.94; 95% CI: 
0.46, 1.43) were independently associated with higher knowledge. Downtown Eastside (DTES) 
residence (i.e., epicenter of Vancouver’s drug scene) was independently associated with lower 
knowledge (β -0.48; 95% CI: -0.81, -0.15). Greater HCV knowledge (β 0.12; 95% CI: 0.07, 0.17) 
was independently associated with higher HCV treatment willingness. DTES residence (β -0.31; 
95% CI: -0.56, -0.06) and daily crack cocaine smoking (β -0.52; 95% CI: -0.92, -0.13) were 
independently associated with lower treatment willingness. 
 
Conclusion: Socioeconomic factors, such as neighborhood residence and employment, were 
associated with HCV knowledge. Higher HCV knowledge was associated with more HCV 
treatment willingness. Our findings suggest that increasing HCV knowledge amongst PWID 
may be an integral component of the HCV cascade of care and that efforts might be best targeted 
to individuals with greater socioeconomic disadvantage. 
 
Word Count: 296  





Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease in 
North America (Kim et al., 2015). People who inject drugs (PWID) compose a large subset of 
individuals infected with HCV (Hajarizadeh, Grebely, & Dore, 2013). Among PWID, up to 90% 
of individuals may be HCV-seropositive (Ng et al., 2013). PWID populations face multiple 
barriers to accessing treatment, with treatment uptake rates ranging from 1.5% to 2.0% per year 
(Alavi et al., 2014; Iversen et al., 2014). Barriers to care are multifactorial at the patient, provider, 
treatment regimen, and health care system levels. Until recently, complex therapy based on 
interferon and ribavirin have presented a significant barrier to treatment. These medications have 
been associated with multiple toxicities and side effects, while associated with low rates of cure 
(Ray & Thomas, 2015).  
Knowledge of HCV transmission, natural history and treatment is believed to be an 
important step in altering transmission risk behaviour, enhancing health maintenance and 
increasing engagement with HCV treatment (Kwiatkowski, Fortuin Corsi, & Booth, 2002). Studies 
have shown that lower HCV knowledge amongst PWID, is linked to socioeconomic factors such 
as lower levels of formal education and non-Caucasian ancestry (Surjadi, Torruellas, Ayala, Yee, 
& Khalili, 2011; Treloar et al., 2011). Conversely, factors associated with increased healthcare 
exposure such as opioid agonist treatment (OAT) and more frequent visits to general practitioners 
have been associated with increased HCV knowledge (Dunn et al., 2013; Treloar et al., 2011). An 
important finding for treatment programs is that willingness to undergo HCV therapy has been 
associated with higher baseline HCV knowledge (Surjadi et al., 2011; Zeremski et al., 2014). 
Understanding which factors are associated with HCV knowledge levels enables 
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development of targeted interventions to enhance HCV knowledge with the ultimate goal of 
increasing treatment uptake and completion.  
Much of the literature to date has examined factors associated with HCV knowledge and 
treatment willingness prior to the current direct acting antiviral (DAA) era. Interventions tailored 
to the needs of PWID will be an important component of efforts to roll out HCV treatment and 
prevention programs. As Interferon sparing DAA-based therapies became widely available in 
Vancouver, Canada beginning in the spring/summer of 2014, the objective of this study was 
to assess HCV knowledge in a cohort of PWID in this setting, between June 2014 and May 2015. 
We aimed to identify factors that were associated with greater HCV knowledge as well as a greater 
willingness to undergo HCV treatment in the current DAA era in order to better inform future 
education and treatment efforts.  
METHODS 
Study design 
The Vancouver Injection Drug Users Study (VIDUS), AIDS Care Cohort to Evaluate 
exposure to Survival Services (ACCESS) and At-Risk Youth Study (ARYS) are open prospective 
cohorts of drug users in Vancouver, Canada. These cohorts, including detailed sampling and 
recruitment procedures, have been described elsewhere (Strathdee et al., 1998; Tyndall et al., 2003; 
Wood et al., 2006). VIDUS enrolls human immunodeficiency virus (HIV)-negative adults (≥18 
years of age) who injected drugs in the month prior to enrolment; ACCESS enrolls HIV-positive 
adults (≥18 years of age) who used illicit drugs (other than or in addition to cannabis) in the month 
prior to enrolment; and ARYS enrolls street-involved youth aged 14-26 years who used illicit 
drugs in the previous month. The primary modes of recruitment in all cohorts are self-referral, 
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word of mouth, and street outreach. Participants are required to reside in the Greater Vancouver 
region at enrolment and provide written informed consent.   
The follow-up procedures for these studies were harmonized to allow for analyses of 
merged data. At baseline and semi-annually thereafter, participants completed an interviewer-
administered questionnaire collecting data on demographics, drug use patterns, healthcare access, 
and other exposures. Venous blood samples were drawn at each visit for HCV and HIV serologic 
testing and HIV disease monitoring as appropriate. Referral for free HIV/AIDS care was provided 
to those found to be HIV positive, and these individuals were subsequently followed in ACCESS. 
In addition, a complete HIV-related clinical profile, including exposure to antiretroviral agents, 
was obtained for all ACCESS participants through a confidential linkage with the provincial Drug 
Treatment Program (Hogg et al., 1998, 2001). Participants were given a stipend ($40 CDN) at each 
study visit. The cohort studies have received annual approval from the University of British 
Columbia/Providence Healthcare Research Ethics Board. 
Participants and HCV knowledge and willingness assessment  
 For this analysis, questionnaire responses collected from June 1, 2014 to May 30, 2015 
were queried for all cohort participants who self-reported ever testing positive for HCV. Those 
who did not report a history of injection drug use or who reported being HCV-seronegative were 
excluded. Self-report was used for exclusion as only those respondents who self-reported being 
HCV-positive were asked specific HCV knowledge and treatment willingness questionnaire items.  
HCV knowledge and treatment willingness were assessed with a series of questions (14 
items) pertaining to HCV transmission, natural history and treatment willingness. These questions 
were developed by local healthcare providers who are involved in the treatment of individuals with 
HCV. Responses were recorded using a Likert scale from 1 (“strongly disagree”) to 5 (“strongly 
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agree”) with most questions worded such that a higher score reflected a greater level of HCV 
knowledge or willingness to participate in HCV therapy. Questions that were worded such that a 
lower numeric response reflected more knowledge or willingness were imputed with a reversed 
scale to allow comparison between questions. Respondents were also permitted to decline 
answering a questionnaire component or to answer “not applicable” or “I don’t know.”  
For the assessment of factors associated with HCV knowledge and treatment willingness, 
participants were excluded if they had missing or inadequate responses (responding “not 
applicable”, “I don’t know” or declining to respond) for at least one question, due to inability to 
calculate consistent total knowledge scores with these responses. For the assessment of factors 
associated with treatment willingness, individuals who had been successfully treated or who were 
on treatment at the time of the questionnaire were also excluded from further analysis. If a 
participant completed two study visits during the study period, we used the most recent observation 
only. 
Study variables  
 The primary outcomes of interest were the composite scores for knowledge and treatment 
willingness, respectively, based on the summation of responses to the remaining questionnaire 
items following a factor analysis [Table 2].  
We considered a range of explanatory variables. Sociodemographic characteristics 
included age (per year older), sex (male vs. female), Caucasian ancestry, ≥high school completion, 
homelessness, Downtown Eastside (DTES) residence, and employment. The DTES is an area in 
Vancouver with an increased density of poverty and illicit substance use. Drug use behaviours 
included ≥daily heroin injection, ≥daily cocaine injection, ≥daily crack smoking, years of injecting 
(per year longer), and heavy alcohol use as defined by the National Institute for Alcohol Abuse 
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and Alcoholism (National Institutes of Health, 2015). Variables assessing healthcare access 
included receipt of OAT, accessing any health or social service, HIV coinfection (stratified by 
≥95% or <95% antiretroviral adherence, as in previous studies) (Milloy et al., 2016), ever 
diagnosed with a mental health disorder, and ever taking HCV treatment. HCV knowledge scores 
were added to the analysis of treatment willingness. All behavioural variables referred to the past 
6 months and were dichotomized as yes vs. no unless otherwise stated. 
We also assessed attitudes towards HCV treatment by asking participants “Which is more 
important to you if you were to consider treatment?” with response options of “How long it lasts” 
or “Types of side effects”.  
Statistical analysis 
Exploratory factor analysis using varimax rotation was used to determine the number of 
factors present among the 14 items, using a maximum likelihood method. These calculations were 
performed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina, USA). Factors 
were then retained if: they had an Eigenvalue of greater than 1 and preceded the elbow in a Scree 
plot, and if the set of items collectively accounted for 70-80% of the variance. Factor loadings 
were used to determine the number of items included within each factor and items with factor 
loading >0.4 were retained. In order to validate an adequate number of parameters for the 
final model, Tucker and Lewis’s reliability coefficient for the maximum likelihood was 
calculated and yielded a score of close to 1 (0.93). This measure is based on the residual 
correlations in the matrix after the effects of final factors are taken out. The coefficient 
ranges from 0 (poorest fit) to 1 (complete fit), therefore a score of 0.93 indicates successful 
choice of questionnaire items. We further calculated Cronbach’s alpha to measure internal 
consistency of the reduced groups, where alpha is a function of the number of items in a test. The 
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final subscales of knowledge and treatment willingness were composed of 6 and 2 items, 
respectively, and had Cronbach’s alpha’s of 0.81 and 0.64. A Cronbach’s alpha of ≥ 0.7 is 
considered good and ≥ 0.6 acceptable (Lance, Butts, & Michels, 2006). The individual item 
scores were combined to come up with the total knowledge and willingness scores (maximum 
scores of 30 and 10, respectively). Both knowledge and willingness were assessed as continuous 
variables using these composite scores with higher scores corresponding to higher knowledge or 
willingness, respectively.  
Next, bivariable and multivariable linear regression analyses were performed to assess 
factors associated with HCV knowledge and willingness to undergo therapy, respectively. We used 
an a priori-defined backward model selection procedure based on examination of the Akaike 
Information Criterion (AIC) and p-values to construct a multivariable model. Specifically, 
variables were included in the full multivariable model if they were significantly associated with 
knowledge or willingness in the bivariable analyses at a p-value of <0.1. After examining the AIC 
of the full model, we removed the variable with the largest p-value and built a reduced model. We 
continued this iterative process until no variables remained for inclusion. We selected the 
multivariable model with the lowest AIC score for each outcome, as previously described 
(Hayashi et al., 2012).   
We examined differences between the sample eligible for the analyses of HCV knowledge 
levels and the group excluded due to inadequate or missing questionnaire responses, using Chi-
squared and Mann-Whitney test. Further, two sensitivity analyses including the group who 
answered “I don’t know” to any knowledge or willingness item were performed by imputing “I 
don’t know” as corresponding to a response of either 1 (“strongly disagree”) or 3 (“neutral”), 
respectively. This was performed due to the concern that participants responding “I don’t 
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know” represented a vulnerable subset of our population and that excluding them from the 
analysis may have biased our findings. This component of the statistical analysis was performed 
using RStudio, version 0.99.892 (R Foundation for Statistical Computing, Vienna, Austria). All p-
values were two-sided. 
RESULTS 
As shown in Figure 1, 1192 PWID who self-reported being HCV-seropositive completed 
a study visit during the study period. Characteristics of the sample are shown in Table 1. Overall 
knowledge level in the total sample (n=1192) was high with mean responses above 4 (“agree”) 
for all six included items [Table 2]. More than 88% of participants correctly answered (4 “agree” 
or 5 “strongly agree”) each included knowledge question item. Mean composite score for HCV 
knowledge amongst 630 questionnaire respondents who answered all questions was 25.41 
(standard deviation [SD]: 2.52) out of 30.  
Willingness to undergo treatment was somewhat lower (<4) compared to knowledge scores 
[Table 2]. Excluding “not applicable” respondents with a history of prior or current 
treatment, 61% of participants “strongly agreed” or “agreed” to consider starting HCV treatment 
within the next year. Of 584 respondents, excluding those previously successfully treated or 
currently on treatment, the mean composite score for treatment willingness was 6.83 (SD: 1.83) 
out of 10.  
Participants were asked additional questions related to treatment willingness which were 
not included in the composite score. When asked if they prioritized treatment duration versus risk 
of side effects, 58% reported risk of side effects as a more important treatment consideration while 
only 16% were more concerned about treatment duration. Fifty-seven percent of participants 
reported that what they have heard about the side effects of HCV treatment scares them. Only 
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66.3% of respondents answered “agree” or “strongly agree” to the question “Treatment for 
hepatitis C can cure the infection in most people”, and 51.3% still believed that HCV treatment 
included a weekly interferon injection.   
Factors Associated with HCV Knowledge 
Six hundred and thirty (53%) participants were included in the analysis of factors 
associated with HCV knowledge level after exclusion of those with missing or inadequate 
responses. The majority of the knowledge sample were male (67%) with a median age of 49.1 
years (interquartile range [IQR]: 42.2-54.9) and were more likely to be HIV-positive compared to 
the missing responses group (p = 0.02). The missing responses group was more likely to be 
homeless, and less likely to have been engaged in HCV care as demonstrated by less contact with 
a physician regarding HCV, fewer HCV specialist referrals, fewer transient elastography 
assessments and less offers of HCV treatment (all p <0.05). Among the 630 participants, 344 
(53%) had ever been offered HCV treatment and of those offered therapy, 58 (17%) had ever 
initiated treatment. 
Factors associated with HCV knowledge levels are shown in Table 3. In multivariable 
analyses, factors independently associated with increased level of HCV knowledge included: 
Caucasian ancestry (adjusted linear regression model estimate [β] 0.50; 95% Confidence Interval 
[CI]: 0.17, 0.82), being employed (β 0.76; 95% CI: 0.38, 1.13), a history of being diagnosed with 
a mental health disorder (β 0.44; 95% CI: 0.44, 0.11), and previous receipt of HCV treatment (β 
0.94; 95% CI: 0.46, 1.43). Attainment of high school education or greater was not associated with 
HCV knowledge (unadjusted β 0.28; 95% CI: -0.06, 0.61). DTES residence was independently 
associated with a lower level of HCV knowledge (β -0.48; 95% CI: -0.81, -0.15). 
Factors Associated with HCV Treatment Willingness 
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Assessment of factors associated with willingness to undergo HCV treatment was 
performed in 584 (49%) individuals after excluding those previously successfully treated or 
currently on treatment. As shown in Table 3, participants were less willing to undergo HCV 
treatment if they resided in the DTES (β -0.31; 95% CI: -0.56, -0.06) or reported at least daily 
crack cocaine smoking (β -0.52; 95% CI: -0.92, -0.13). A greater degree of HCV knowledge was 
associated with an increased willingness to pursue HCV treatment (β 0.12; 95% CI: 0.07, 0.17). 
Sensitivity Analysis 
 The results of sensitivity analyses were largely unchanged from the planned analysis. The 
only difference was that older age was associated with lower HCV knowledge (β -0.02; 95% CI: -
0.04, -0.01), and that DTES residence was no longer independently associated with low treatment 
willingness (β -0.23; 95% CI: -0.44, -0.03; p=0.06). 
DISCUSSION 
 Overall, we found a high level of HCV knowledge amongst our sample of PWID. 
Caucasian ancestry, employment and residence outside the DTES were independently associated 
with greater HCV knowledge implying a possible impact of socioeconomic and structural barriers 
upon knowledge acquisition. Greater healthcare exposure was associated with higher HCV 
knowledge scores while DTES residence and daily crack cocaine smoking were associated with 
less willingness to initiate HCV treatment. A one point increase in the composite HCV 
knowledge score was associated with a 0.1 point increase in the score of willingness to initiate 
HCV treatment, however, study participants cited concerns regarding treatment side effects as 
being a major barrier. Knowledge of high sustained virologic response (SVR) rates and the 
interferon-sparing nature of DAA regimens appeared to be limited and this may have contributed 
to the cohort having only modest willingness to initiate HCV treatment.  
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 Previous studies, mostly conducted prior to the current DAA era, have shown varying 
levels of HCV knowledge amongst their populations. These studies have used different 
questionnaires to attempt to assess HCV knowledge and have evaluated diverse populations with 
or without a history of HCV infection or injection drug use, respectively (Cohen-Moreno et al., 
2010; Dunn et al., 2013; Stein, Maksad, & Clarke, 2001; Strauss et al., 2007; Surjadi et al., 2011; 
Treloar, Hull, Dore, & Grebely, 2012; Zeremski et al., 2014). Among these studies, baseline 
average HCV knowledge scores were reported to range from 42-71% with lower scores generally 
reported in studies using more rigorous assessment tools. While heterogeneous assessment tools 
used across the studies do not permit direct comparison, knowledge amongst our sample appeared 
to be high relative to prior studies possibly reflecting cumulative population knowledge as HCV 
treatment efforts have scaled up over the years.   
Caucasian ancestry was associated with greater HCV knowledge, with the second 
largest ancestral grouping amongst our study participants being comprised of individuals of 
Indigenous heritage. Within the social constructs that exist in our study setting, individuals 
of Caucasian ancestry may face fewer structural barriers thus enhancing their ability to 
acquire HCV knowledge. This finding also suggests that both assessment of HCV knowledge 
and provision of HCV education may benefit from attention to the cultural competence of 
providers.  
Not surprisingly, previous HCV treatment was associated with increased HCV knowledge. 
Individuals with a history of HCV treatment would have had multiple HCV-specific healthcare 
encounters, accounting for their higher knowledge levels. Similarly, participants with a diagnosis 
of a mental health disorder would also have more frequent healthcare contact, which may have 
provided the opportunity for education surrounding HCV. Treatment with interferon based therapy 
 13 
is generally contraindicated in comorbid mental health disorders. Providers caring for this 
population may be more attuned to the advancements in interferon-sparing therapy for this reason, 
and thus may have discussed this option more readily with this group of participants. Frequency 
of healthcare contacts has also been associated with greater knowledge levels in previous studies 
(Dunn et al., 2013; Marshall et al., 2015; Treloar et al., 2011).   
Based on prior studies, we had anticipated that HIV co-infection and OAT would be 
associated with HCV knowledge levels in our sample. However, this was not demonstrated in our 
analyses. The historically poor treatment response rates to interferon and ribavirin combination 
therapy, particularly in HIV co-infected individuals (Chung et al., 2004), may have resulted in 
HIV providers prioritizing other health concerns over HCV thus potentially explaining why those 
co-infected with HIV did not have an increased level of HCV knowledge despite more intense 
healthcare contact.  
Daily crack smoking was associated with less willingness to undergo HCV treatment, as 
was DTES residence. The physiologic effects of crack cocaine intoxication may contribute to the 
association of daily crack cocaine smoking with lower HCV treatment willingness (Fischer et al., 
2015). As well, given the silent nature of chronic HCV infection (Smith, Combellick, Jordan, & 
Hagan, 2015), competing health and socioeconomic priorities may supersede individual interest in 
HCV treatment among some individuals living in the DTES.  
Consistent with previous studies (Norton et al., 2014; Surjadi et al., 2011; Zeremski et al., 
2014), we found that a greater knowledge of HCV was associated with an increased willingness 
to undergo HCV therapy. These same studies have also demonstrated that educational 
interventions can increase participant knowledge levels as well as increase treatment willingness 
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and subsequent follow up attendance at specialist clinics suggesting that knowledge does in fact 
play a role in willingness to undergo therapy.  
HCV treatment willingness in populations similar to ours have been reported to be as high 
as 97% in the pre-DAA era (Surjadi et al., 2011). While greater HCV awareness amongst PWID 
may explain our participants’ high knowledge scores, this may also contribute to less willingness 
to initiate HCV treatment in our population due to the greater appreciation of treatment side effects 
from interferon containing regimens. This is supported by the finding that a significant proportion 
of our sample expressed concern regarding the risk of side effects from HCV therapy. Although 
specific knowledge questions in our final knowledge score did not address HCV treatment side 
effects, this finding suggests that the significantly improved side effect profile of the new 
interferon-sparing DAA regimens is likely an important knowledge gap to target in future 
educational interventions. Further, educational interventions targeting the paradigm shift in HCV 
treatment with respect to both improved tolerability and treatment success need to be prioritized 
in order to increase treatment enthusiasm amongst PWID.  
Our study represents one of the largest cohort studies focused on assessing correlates of 
HCV knowledge and treatment willingness in PWID. The main limitation in our study was the 
lack of a validated HCV knowledge assessment tool. No single tool exists to assess an individual’s 
knowledge of HCV, making comparison of the findings of individual studies difficult. However, 
our findings identified similar factors and themes associated with a greater or lesser degree of HCV 
knowledge amongst PWID as seen in previous studies, suggesting that these various methods of 
knowledge assessment are in fact measuring similar constructs (Grau, Zhan, & Heimer, 2016; 
Marshall et al., 2015; Surjadi et al., 2011). A second limitation was that a large number of study 
participants answered “I don’t know” or declined to answer at least one of the knowledge 
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questions. This group with missing or inadequate responses was significantly different from the 
final analytical sample in both socioeconomic factors and access to care. However, we note that 
sensitivity analyses did not significantly change our results. Thirdly, reporting bias in the self-
reported data and the possibility of unidentified confounders, as occurs in all observational studies, 
were additional sources of limitations. Finally, non-random sampling methods used in our cohorts 
may limit the generalizability of our findings.    
 In summary, our study identified several socioeconomic and structural factors to be 
associated with both HCV knowledge and treatment willingness, suggesting that addressing the 
underlying structural inequality facing PWID is likely to represent an important aspect of HCV 
treatment rollout. As interferon sparing DAA-based therapies were introduced near the beginning 
of the study period, wide-spread community awareness of these new therapies was likely limited, 
as reflected in our findings of more modest knowledge pertaining to these treatments. Our findings 
suggest that it will be important for HCV programs to continue to focus on education, with an 
emphasis on the substantial improvement in side effect profiles and SVR rates of the current DAA 
treatments if expansion of HCV therapy amongst PWID is to be accomplished.  
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Table 1: Characteristics of self-reported HCV positive people who inject drugs in the VIDUS, 
ACCESS and ARYS cohorts, June 1, 2014 to May 30, 2015 (n = 1192). 
 
Table 2: Summary scores of the HCV knowledge and willingness to undergo HCV treatment 
scales amongst HCV positive people who inject drugs in Vancouver, Canada (n = 1192). 
 
Table 3: Bivariable and multivariable linear regression of factors associated with HCV 
knowledge and willingness to undertake treatment among HCV-positive people who inject 
drugs in Vancouver, Canada (2014-2015). 
 
Figure 1: Determination of analytic samples. 
